Management of vasovagal syncope

Journal of Cardiovascular Electrophysiology

Volumn 10, Issue 6, 1999, Pages 874-886

  Atiga, Walter L ^a   Rowe, Peter ^a,b   Calkins, Hugh ^b  

^a Department of Medicine Pediatrics ^*  (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neurally mediated syncope; Neurocardiogenic syncope; Vasodepressor; Vasovagal syncope

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEXAMPHETAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; FLUDROCORTISONE; MIDODRINE; PROPANTHELINE BROMIDE; PSEUDOEPHEDRINE; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE;

ADULT; AUTONOMIC DYSFUNCTION; CASE REPORT; FEMALE; HEAD TILTING; HEART PACING; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYNCOPE;

EID: 0033030337     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1999.tb00270.x     Document Type: Review

References (83)

1. 1. Linzer M, Pontinen M, Gold D, et al: Impairment of physical and psychosocial function in recurrent syncope. J Clin Epidemiol 1991;44:1037-1043.
2. 2. Calkins H, Byrne M, El-Atassi R, et al: The economic burden of unrecognized vasodepressor syncope. Am J Med 1993;95:473-479.
3. 3. Gowers WR: A lecture on vagal and vasovagal attacks. Lancet 1907;173:1551-1553.
4. 4. Lewis T: A lecture on vasovagal syncope and the carotid sinus mechanism: With comments on Gower's and Nothnagel's syndrome. Br Med J 1932;1:873-876.
5. 5. Allen SC, Taylor CL, Hall VE: A study of orthostatic insufficiency by the tilt board method. Am J Physiol 1945;143:11-20.
6. 6. Wieling W, Lieshout J: Maintenance of postural normotension in humans. In Low P, ed: Clinical Autonomic Disorders. Little, Brown, and Company, Boston, 1997, pp. 73-82.
7. 7. Kenny RA, Ingram A, Bayliss J, et al: Head-up tilt: A useful test for investigating unexplained syncope. Lancet 1986;2:1352-1354.
8. 8. Calkins H, Seifert M, Morady F: Clinical presentation and long term follow-up of athletes with exercise induced vasodepressor syncope. Am Heart J 1995;129: 1159-1164.
9. 9. Tseng CJ, Tung CS: Brainstem and cardiovascular regulation. In Robertson D, Biaggioni I, eds: Disorders of the Autonomic Nervous System. Harwood Academic Publishers, London, 1995, pp. 9-24.
10. 10. Smith ML, Carlson MD, Thames MD: Reflex control of the heart and circulation: Implications for cardiovascular electrophysiology. J Cardiovasc Electrophysiol 1991;2:441-449.
11. 11. Sra J, Jazayeri M, Murthy V, et al: Sequential catecholamine changes during upright tilt: Possible hormonal mechanisms responsible for pathogenesis of neurocardiogenic syncope. J Am Coll Cardiol 1991;17:216A.
12. 12. Waxman MB, Asta JA, Cameron DA: Vasodepressor reaction induced by inferior vena cava occlusion and isoproterenol in the rat. Circulation 1994;89:2401-2411.
13. 13. Benarroch E: The central autonomic network: Functional organization, dysfunction, and perspective. Mayo Clin Proc 1993;68:988-1001.
14. 14. Chosy JJ, Graham DT: Catecholamines in vasovagal fainting. J Psychosom Res 1965;89:2401-2411.
15. 15. Rea R, Thames M: Neural control mechanisms and vasovagal syncope. J Cardiovasc Electrophysiol 1993; 4:587-595.
16. 16. Lofring V: Cardiovascular adjustments induced from the rostral cingulate gyrus: With specific reference to sympatho-inhibiting mechanisms. Acta Physiol Scand 1961;51(Suppl 184):5-82.
17. 17. Fitzpatrick AP, Banner N, Cheng A, et al: Vasovagal syncope may occur after orthotopic heart transplantation. J Am Coll Cardiol 1993;21:1132-1137.
18. 18. Lightfoot JT, Rose SA, Fortney SM: Occurrence of presyncope in subjects without ventricular innervation. Clin Sci 1993;85:695-700.
19. 19. Thompson WO, Thompson PK, Dailey ME: The effect of posture upon the composition and volume of the blood in man. J Clin Invest 1988;5:573-609.
20. 20. Pema GP, Ficola U, Salvatori P, et al: Increase of plasma â-endorphins in vasodepressor syncope. Am J Cardiol 1990;65:929-930.
21. 21. Wallbridge DR, MacIntyre HE, Gray CE, et al: Increase in plasma å-endorphins precedes vasodepressor syncope. Br Heart J 1994;71:446-448.
22. 22. Evans RG, Ludbrook J, Potonick SJ: Intracisternal naloxone and cardiac nerve blockade prevent vasodilation during simulated haemorrhage in awake rabbits. J Physiol (Lond) 1989;409:1-14.
23. 23. Ferguson DW: Naloxone potentiates cardiopulmonary baroreflex sympathetic control in normal humans. Circ Res 1992;70:172-183.
24. 24. Elam RF, Bergman F, Feverstein G: The use of antiserotonergic agents for the treatment of acute hemorrhagic shock in cats. Eur J Pharmacol 1985;107:275-278.
25. 25. Baum T, Shropshire AT: Inhibition of efferent sympathetic nerve activity by 5-hydroxytryptophan in centrally administered 5-hydroxytryptamine. Neuropharmacology 1975;14:227-233.
26. 26. Tadepelli A, Mills E, Schanberg S: Central depression of carotid baroreceptor response, arterial pressure, and heart rate by 5-hydroxytryptophan. J Pharmacol Exp Ther 1977;202:310-319.
27. 27. Abboud FM: Neurocardiogenic syncope. N Engl J Med 1993;328:1117-1119.
28. 28. Hjorth S: Penbutolol as a blocker of central 5HT1A receptor-mediated responses. Eur J Pharmacol 1992; 222:121-127.
29. 29. Benditt DG, Ferguson DW, Grubb BP, et al: Tilt table testing for assessing syncope. J Am Coll Cardiol 1996; 28:263-275.
30. 30. Grubb BP, Kosinski D: Tilt table testing: Concepts and limitations. PACE 1997;20(Pt II):781-787.
31. 31. Mahanonda N, Bhuripanyo K, Kangkagate C, et al: Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results. Am Heart J 1995; 130:1250-1253.
32. 32. Sheldon R, Rose S, Flanagan P, et al: Effect of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test. Am J Cardiol 1996;78:536-539.
33. 33. Slotwiner DJ, Stein KM, Lippman N, et al: Response of neurocardiac syncope to beta-blocker therapy: Interaction between age and parasympathetic tone. PACE 1997;20(Pt II):810-814.
34. 34. Scott WA, Giacomo P, Bromberg BI, et al: Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope. Am J Cardiol 1995;76:400-402.
35. 35. Biffi M, Boriani G, Sabbatani P, et al: Malignant vasovagal syncope: A randomised trial of metoprolol and clonidine. Heart 1997;77:268-272.
36. 36. Klingenheben T, Kalusche D, Yi-Gang L, et al: Changes in plasma epinephrine concentration and in heart rate during head-up tilt testing in patients with neurocardiogenic syncope: Correlation with successful therapy with â-receptor antagonists. J Cardiovasc Electrophysiol 1996;7:802-808.
37. 37. Cox MM, Perlman BA, Mayor MR, et al: Acute and long-term â-adrenergic blockade for patients with neurocardiogenic syncope. J Am Coll Cardiol 1995;26: 1293-1298.
38. 38. Cohen MB, Snow JS, Grasso V, et al: Efficacy of pindolol for treatment of vasovagal syncope. Am Heart J 1995;13:780-790.
39. 39. Sra JS, Murthy VS, Jazayeri MR, et al: Use of intravenous esmolol to predict efficacy of oral beta-adrenergic blocker therapy in patients neurocardiogenic syncope. J Am Coll Cardiol 1992;19:402.
40. 40. Grubb BP, Temesy-Armos P, Moore J, et al: The use of head-upright tilt table testing in the evaluation and management of syncope in children and adolescents. PACE 1992;15:742.
41. 41. Natale A, Sra J, Dhala A, et al: Efficacy of different treatment strategies for neurocardiogenic syncope. PACE 1995;18(Pt I):655-662.
42. 42. Bannister R: Multiple system atrophy and pure autonomic failure. In Low P, ed: Clinical Autonomic Disorders. Little Brown Co., Boston, 1993, pp. 517-525.
43. 43. Mion D, Rea R, Anderson E, et al: Effects of fludrocortisone on sympathetic nerve activity in humans. Hypertension 1994;23:123-130.
44. 44. Balaji S, Oslizlok PC, Allen MC, et al: Neurocardiogenic syncope in children with a normal heart. J Am Coll Cardiol 1994;23:779-785.
45. 45. Morillo CA, Leitch JW, Yee R, et al: A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt. J Am Coll Cardiol 1993;22:1843-1848.
46. 46. Milstein S, Buetikofer J, Dunnigan A, et al: Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia. Am J Cardiol 1990:65:1339-1344.
47. 47. Leor J, Rotstein Z, Vered Z, et al: Absence of tachycardia during tilt test predicts failure of beta-blocker therapy in patients with neurocardiogenic syncope. Am Heart J 1994;127:1539-1543.
48. 48. Sra JS, Jazayeri MR, Avitall B, et al: Comparison of cardiac pacing with drug therapy in the treatment of neurocardiogenic (vasovagal) syncope with bradycardia or asystole. N Engl J Med 1993;328:1085-1090.
49. 49. Grubb BP, Wolfe DA, Samoil D, et al: Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope. PACE 1993;16(Pt I):458-464.
50. 50. Grubb BP, Samoil D, Kosinski D, et al: Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents. J Am Coll Cardiol 1994;24:490-494.
51. 51. Lenk M, Alehan D, Ozme S, et al: The role of serotonin re-uptake inhibitors in preventing recurrent unexplained childhood syncope - A preliminary report. Eur J Pediatr 1997;156:747-750.
52. 52. Tandan T, Giuffre M, Sheldon R: Exacerbation of neurally mediated syncope associated with sertraline. Lancet 1997;349:1145-1146.
53. 53. Jankovic J, Hiner BC, Brown DC: Neurogenic orthostatic hypotension: A double-blind, placebo-controlled study with midodrine. Am J Med 1993;95:38-48.
54. 54. Erhringer H: Studies on the peripheral haemodynamics in man after intravenous infusion of a small dose of di-1-(2 prime, 5 prime-dimethoxyphenyl)-2-glycin-amido-ethanol-(1)-hydrochloride. Int J Clin Pharmacol Ther Toxicol 1971;4:415-420.
55. 55. Ward CR, Gray JC, Gilroy JJ, et al: Midodrine: A role in the management of neurocardiogenic syncope. Heart 1998;79:45-49.
56. 56. Sra J, Maglio C, Biehl M, et al: Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy. J Cardiovasc Electrophysiol 1997; 8:42-46.
57. 57. Strieper MJ, Campbell RM: Efficacy of alpha-adrenergic agonist therapy for prevention of pediatric neurocardiogenic syncope. J Am Coll Cardiol 1993;22:594-597.
58. 58. Raviele A, Themistoclakis S, Gasparini G: Drug treatment of vasovagal syncope. In Blanc J-J, Benditt D, Sutton R, eds; Neurally Mediated Syncope: Pathophysiology, Investigations, and Treatment. Futura Publishing Company, Inc., Armonk, NY, 1996, pp. 113-117.
59. 59. Vasovagal Syncope International Study (VASIS) Group: Double-blind randomised study of etilefrine versus placebo in patients with tilt-induced recurrent vasovagal syncope. Eur J Card Pacing Electrophysiol 1993;3:164.
60. 60. Grubb BP, Kosinski D, Mouhaffel A, et al: The use of methylphenidate in the treatment of refractory neurocardiogenic syncope. PACE 1996;19:836-840.
61. 61. Susmano A, Volgman AS, Buckingham TA: Beneficial effects of dextro-amphetamine in the treatment of vasodepressor syncope. PACE 1993;16:1235-1239.
62. 62. Lopez CJ, Pico AF, Sanchez MJ, et al: Malignant vasovagal syncope: Its diagnosis and therapeutic trial based on the orthostatism test (the tilt-table test). Rev Esp Cardiol 1993;46:28-33.
63. 63. Grubb BP, Temesy-Armos P, Hahn H, et al: Utility of upright tilt table testing in the evaluation and management of syncope of unknown origin. Am J Med 1991; 90:6-10.
64. 64. Lee TM, Su SF, Chen MF, et al: Usefulness of transdermal scopolamine for vasovagal syncope. Am J Cardiol 1996;78:480-482.
65. 65. Yu JC, Sung RJ: Clinical efficacy of propantheline bromide in neurocardiogenic syncope: Pharmacodynamic implications. Cardiovasc Drugs Ther 1997;10: 687-792.
66. 66. Corbala F, Pacheco UA, Pedraza IS, et al: Vasovagal syncope: Management with propantheline bromide. Arch Inst Cardiol Mex 1997;67:227-230.
67. 67. Nelson SD, Stanley M, Love CJ, et al: The autonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope. Arch Intern Med 1991;151:2425.
68. 68. Lee TM, Chen MF, Su SF, et al: Excessive myocardial contraction in vasovagal syncope demonstrated by echocardiography during head-up tilt test. Clin Cardiol 1996;19:137-140.
69. 69. van Valdhuisen DJ, Brodde OE, van Gilst WH, et al: Relation between myocardial beta-adrenoceptor density and hemodynamic and neurohumoral changes in a rat model of chronic myocardial infarction: Effects of ibopamine and captopril. Cardiovasc Res 1995;30:386-393.
70. 70. Zeng C, Zhu Z, Liu G, et al: Randomized, double-blind, placebo-controlled trial of oral enalapril in patients with neurally mediated syncope. Am Heart J 1998;136:852-858.
71. 71. El-Sayed H, Hainsworth R: Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope. Heart 1996;75:134-140.
72. 72. Younoszai AK, Franklin WH, Chan DP, et al: Oral fluid therapy: A promising treatment for vasodepressor syncope. Arch Pediatr Adolesc Med 1998;152:165-168.
73. 73. Petersen MEV, Chamberlain-Weber R, Fitzpatrick A, et al: Permanent pacing for cardioinhibitory malignant vasovagal syncope. Br Heart J 1994;71:274-281.
74. 74. Fitzpatrick A, Sutton R: Tilting toward a diagnosis in recurrent unexplained syncope. Lancet 1989;1: 658-660.
75. 75. Fitzpatrick A, Theodorakis G, Ahmed R, et al: Dual chamber pacing aborts vasovagal syncope induced by head up 60° tilt. PACE 1991;14:13-19.
76. 76. Samoil D, Grubb BP, Brewster P, et al: Comparison of single and dual chamber pacing techniques in the prevention of upright tilt-induced vasovagal syncope. Eur J Card Pacing Electrophysiol 1993;3:36-41.
77. 77. Connolly SJ, Sheldon R, Roberts RS, et al, on behalf of the Vasovagal Pacemaker Study Investigators: The North American Vasovagal Pacemaker Study (VPS): A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. Circulation 1999;33: 16-20.
78. 78. Gamachie C, Janosik D, Redd R, et al: Long-term outcome of head up tilt guided therapy patients with neurally mediated syncope. PACE 1991;14:663A.
79. 79. Sra JS, Anderson AJ, Sheikh SH, et al: Unexplained syncope evaluated by electrophysiologic studies and head up tilt testing. Ann Intern Med 1991;114:1013-1019.
80. 80. Fitzpatrick A, Theodorakis G, Travill C, et al: Incidence of the malignant vasovagal syndrome in patients with recurrent syncope. Eur Heart J 1992;12:389-394.
81. 81. Epstein AE, Miles WM, Benditt DG: Personal and public safety issues related to arrhythmias that may affect consciousness: Implications for regulation and physician recommendations. An AHA/NASPE Medical Scientific Statement. Circulation 1996;94:1146-1166.
82. 82. Consensus Conference, Canadian Cardiovascular Society: Assessment of the cardiac patient for fitness to drive. Can J Cardiol 1992;8:406-412.
83. 83. Calkins H, Shyr Y, Frumin H, et al: The value of the clinical history in the differentiation of syncope due to ventricular tachycardia, atrioventricular block, and vasodepressor syncope. Am J Med 1995;98:365-373.